Rafael Holdings (RFL)

A key focus is Trappsol Cyclo, a therapy being studied for Niemann-Pick Disease Type C1, a rare and serious genetic disorder that affects cellular cholesterol transport. The program is in Phase 3 clinical trials, and Rafael’s strategy centers on advancing development, supporting the regulatory pathway, and preparing for potential commercialization if approvals are obtained. As with many biotechnology companies, the value of this asset depends heavily on clinical results, regulatory review, funding needs, and the size of the addressable patient population.

Rafael also holds interests in portfolio companies that pursue therapeutics and medical technologies for areas of unmet medical need. These include companies such as Cyclo, LipoMedix, Rafael Medical Devices, Barer, Cornerstone, and Day Three. The portfolio spans drug development and device-related opportunities, which can diversify scientific exposure but also introduces the risks typical of early-stage healthcare investing.

The company reports through Healthcare, Infusion Technology, and Real Estate segments. The real estate component reflects legacy assets and helps distinguish Rafael from a conventional biotech developer, although its investment case is primarily shaped by progress across its healthcare holdings. Investors generally evaluate Rafael based on clinical milestones, capital allocation, regulatory prospects, partnership potential, and the ability of its portfolio companies to convert research programs into approved and commercially viable products.